Loading…
OABI
OmniAb, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 68218J103
$4.59-2.96%Price as of Oct 17, 12:03 UTC · updated once a day, after the close
At a glance
OmniAb, Inc. (OABI) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in EmeryVille, United States and has 89 employees. The company is worth $667.34M. Revenue was $18.67M in fiscal 2025, down 29.3% from the year before. It reported a net loss of $64.78M. The share price is 15.5% below its 52-week high of $5.43. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $1.62M. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $667.34M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.6x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.36
- ROE
- -16.95%
- Profit margin
- -115.12%
- Revenue growth
- +244.20%
- Beta
- 1.37
- 52-week high
- $5.43
- 52-week low
- $1.30
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Two SigmaHeldTwo Sigma Investments · Q2 2026$1.62M657.43K shares · 0.0% of portfolio
- Renaissance TechnologiesHeldRenaissance Technologies · Q2 2026$1.48M600.35K shares · 0.0% of portfolio
- Israel EnglanderHeldMillennium Management · Q2 2026$864.31K474.16K shares · 0.0% of portfolio
- Cliff AsnessHeldAQR Capital Management · Q2 2026$387.98K157.72K shares · 0.0% of portfolio
Ken GriffinHeldCitadel Advisors · Q2 2026$143.15K58.19K shares · 0.0% of portfolio
Price over time
▼ -54.1% over 5Y.
today you would have $459.46▼ -54.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.85 | $3.54 | $6.17 | $3.60 | $10.00 | |
| P/S | 15.4x | 14.3x | 16.4x | 21.2x | 7.0x | — |
| P/B | 1.4x | 1.0x | 1.5x | 2.3x | 1.2x | — |
| EPS | -$0.57 | -$0.61 | -$0.51 | -$0.26 | -$0.33 | |
| Profit margin | -148.16% | -347.04% | -235.05% | -148.16% | -37.80% | -77.82% |
| ROE | -16.09% | -24.26% | -21.57% | -16.09% | -6.54% | -11.54% |
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AURAAura Biosciences, Inc. | $6.46 | — | 2.1x | 0.00% | -53.48% | $669.93M |
| SLDBSolid Biosciences Inc. | $6.19 | — | 1.7x | 0.00% | -65.50% | $663.72M |
| LXRXLexicon Pharmaceuticals Inc | $1.49 | — | 3.8x | 0.00% | -40.21% | $662.98M |
| PHARPharming Group N.V. | $9.36 | 72.0x | 2.5x | 0.00% | 3.65% | $662.48M |
| IMMXImmix Biopharma, Inc. | $7.98 | — | 2.5x | 0.00% | -34.18% | $661.57M |
| WVEWave Life Sciences, Inc. | $3.35 | — | 1.4x | 0.00% | -67.42% | $660.11M |
About the company
- 89
- EmeryVille, United States